Arctoris was featured by Medicines Discovery Catapult following its collaboration with Intelligent OMICS and Medicines Discovery Catapult on a pioneering Innovate UK-backed project combining artificial intelligence, machine learning and automated biology to accelerate drug discovery.
The project focuses on identifying novel disease targets and candidate drugs for lung cancer, specifically within the KRAS signalling pathway. Intelligent OMICS uses advanced in silico (computer-based) tools to analyse transcriptomic and molecular data, uncovering previously hidden components of disease biology and identifying new druggable targets that conventional methods might miss.
Arctoris plays a critical role in the collaboration by using its automated drug discovery platform in Oxford to run the biological assays that experimentally validate the targets identified through Intelligent OMICS’ AI-driven pipeline. Medicines Discovery Catapult contributes cheminformatics expertise, identifying the most appropriate chemical tools and leads to test against the newly uncovered targets.
Together, the partners aim to demonstrate a fully integrated in silico to wet lab pipeline which offers a compelling proof point for how machine learning, robotics and biology can work in concert to deliver faster, more cost-effective drug discovery.
If successful, the partnership will have validated an entirely new approach to drug discovery, with the potential to scale across multiple pathways and disease areas, ultimately accelerating the development of new treatments for patients worldwide.
Read the full article